ArticleAntimicrobial agents and chemotherapy2007
Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2.
Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 66 citations in OpenAlex.
- Putative azithromycin resistance mutations inAntimicrobial agents and chemotherapy · 2026Article
- Azithromycin alters the microbiome composition, function and resistome in women with Chlamydia trachomatis infections.NPJ biofilms and microbiomes · 2025Article
- Evolutionary dynamics in the genome of ocularMicrobial genomics · 2025Article
- Phenotypic and Genotypic Antimicrobial Susceptibility Testing ofAntibiotics (Basel, Switzerland) · 2023Article
- Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment ofJournal of enzyme inhibition and medicinal chemistry · 2022Article
- Direct assessment of possible mutations in the 23S rRNA gene encoding macrolide resistance in Chlamydia trachomatis.PloS one · 2022Article
- Tigecycline in the treatment of severe pneumonia caused byFrontiers in medicine · 2022Review
- Repeat infections with chlamydia in women may be more transcriptionally active with lower responses from some immune genes.Frontiers in public health · 2022Article
- An overview of genes and mutations associated with Chlamydiae species' resistance to antibiotics.Annals of clinical microbiology and antimicrobials · 2021Review
- Chlamydial clinical isolates show subtle differences in persistence phenotypes and growthAccess microbiology · 2021Article
- Detection and identification ofIranian journal of microbiology · 2020Article
- Bioactive Compounds ofMicroorganisms · 2019Article
- Repurposing salicylamide for combating multidrug-resistantAntimicrobial agents and chemotherapy · 2019Article
- Dynamic energy dependency ofThe Journal of biological chemistry · 2018Article
- Beyond Tryptophan Synthase: Identification of Genes That Contribute to Chlamydia trachomatis Survival during Gamma Interferon-Induced Persistence and Reactivation.Infection and immunity · 2016Article
- Review
- Pathogenic Chlamydia Lack a Classical Sacculus but Synthesize a Narrow, Mid-cell Peptidoglycan Ring, Regulated by MreB, for Cell Division.PLoS pathogens · 2016Article
- Differences in 23S ribosomal RNA mutations between wild-type and mutant macrolide-resistantExperimental and therapeutic medicine · 2015Article
- Detection of Chlamydophila psittaci from pigeons by polymerase chain reaction in Ahvaz.Iranian journal of microbiology · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Azithromycin is a major drug used in the treatment and prophylaxis of chlamydial infections. Spontaneous azithromycin-resistant mutants of Chlamydia psittaci 6BC were isolated in vitro in the plaque assay at a frequency of about 10(-8). Isogenic clonal variants with A(2058)C, A(2059)G, or A(2059)C mutations in the unique 23S rRNA gene (Escherichia coli numbering system) displayed MICs for multiple macrolides (i.e., azithromycin, erythromycin, josamycin, and spiramycin) at least 100 times higher than those of the parent strain and were also more resistant to the lincosamide clindamycin. Chlamydia trachomatis L2 variants with a Gln-to-Lys substitution in ribosomal protein L4 at position 66 (E. coli numbering system), conferring an eightfold decrease in azithromycin and erythromycin sensitivities and a fourfold decrease in josamycin and spiramycin sensitivities, were isolated following serial passage in subinhibitory concentrations of azithromycin. Each mutation was stably maintained in the absence of selection but severely affected chlamydial infectivity, as determined by monitoring the development of each isolate over 46 h in the absence of selection, in pure culture or in 1:1 competition with the isogenic parent. Data in this study support the hypothesis that the mechanisms which confer high-level macrolide resistance in chlamydiae carry a prohibitive physiological cost and may thus limit the emergence of highly resistant clones of these important pathogens in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.